Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 3 | 1 | 4 |
| 1997 | 3 | 2 | 5 |
| 1998 | 1 | 1 | 2 |
| 1999 | 4 | 0 | 4 |
| 2000 | 4 | 0 | 4 |
| 2001 | 4 | 1 | 5 |
| 2002 | 1 | 0 | 1 |
| 2003 | 6 | 1 | 7 |
| 2004 | 4 | 3 | 7 |
| 2005 | 5 | 5 | 10 |
| 2006 | 4 | 4 | 8 |
| 2007 | 4 | 2 | 6 |
| 2008 | 7 | 4 | 11 |
| 2009 | 6 | 1 | 7 |
| 2010 | 4 | 4 | 8 |
| 2011 | 11 | 3 | 14 |
| 2012 | 4 | 1 | 5 |
| 2013 | 4 | 1 | 5 |
| 2014 | 3 | 1 | 4 |
| 2015 | 5 | 2 | 7 |
| 2016 | 6 | 2 | 8 |
| 2017 | 7 | 3 | 10 |
| 2018 | 7 | 0 | 7 |
| 2019 | 12 | 3 | 15 |
| 2020 | 4 | 4 | 8 |
| 2021 | 4 | 8 | 12 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Adv. 2023 12 26; 7(24):7393-7401.
-
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma. Blood Adv. 2023 12 12; 7(23):7361-7368.
-
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study. Blood Adv. 2023 09 12; 7(17):5038-5046.
-
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 2023 06 13; 7(11):2287-2296.
-
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial. JAMA Oncol. 2023 05 01; 9(5):683-691.
-
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. Am J Hematol. 2023 06; 98(6):900-912.
-
Melphalan flufenamide for relapsed/refractory multiple myeloma. Drugs Today (Barc). 2022 Aug; 58(8):407-423.
-
Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. Eur J Cancer. 2022 08; 171:183-192.
-
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2022 10 01; 40(28):3289-3300.
-
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 05 01; 8(5):740-747.